Jonathan Heller

Jonathan has been leading the development of new medicines for over 15 years. He was most recently responsible for external R&D in the Rare Disease group at Pfizer. Prior to that he led drug development teams at Alexion, Synageva, and BioMarin. Jonathan began his career as a co-founder of Erimos Pharmaceuticals - a startup oncology business. He has a PhD in Biology from The Johns Hopkins University and an MBA from The University of California Berkeley Haas School of Business.